Guardant Health, Inc. (GH) News

Guardant Health, Inc. (GH): $52.47

-2.57 (-4.67%)

POWR Rating

Component Grades













Filter GH News Items

GH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GH News Highlights

  • For GH, its 30 day story count is now at 36.
  • Over the past 23 days, the trend for GH's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
  • FLEX, CVS and BASE are the most mentioned tickers in articles about GH.

Latest GH News From Around the Web

Below are the latest news stories about Guardant Health Inc that investors may wish to consider to help them evaluate GH as an investment opportunity.

Guardant Health, Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 24, 2022

Why Guardant Health Stock Zoomed 10% Higher Today

It was all about the earnings for the cancer-diagnostics specialist.

The Motley Fool | February 24, 2022

Guardant Health Non-GAAP EPS of -$0.69 beats by $0.39, revenue of $108.11M beats by $9.39M

Guardant Health press release (NASDAQ:GH): Q4 Non-GAAP EPS of -$0.69 beats by $0.39. Revenue of $108.11M (+38.0% Y/Y) beats by $9.39M. Adjusted EBITDA loss was $64.6 million for the fourth quarter of 2021, as compared to a $29.7 million loss Y/Y. Guardant Health expects full year 2022 revenue to be...

Seeking Alpha | February 23, 2022

Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter and year ended December 31, 2021. Recent Highlights Revenue of $108 million for the fourth quarter of 2021 and $374 million for the full year 2021, an increase of 38% and 30% over the corresponding period of 2020 Repor

Business Wire | February 23, 2022

Guardant Health, Inc. (GH) Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 23, 2022

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of 21.24% and 9.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Charles River (CRL) to Report Q4 Earnings: What's in Store?

The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.

Yahoo | February 11, 2022

Nvwm, Llc Buys Vanguard Ultra-Short Bond ETF, Vanguard Total Stock Market ETF, Vanguard Mega ...

Investment company Nvwm, Llc (Current Portfolio) buys Vanguard Ultra-Short Bond ETF, Vanguard Total Stock Market ETF, Vanguard Mega Cap Growth ETF, Vanguard Total International Stock, Freeport-McMoRan Inc, sells Quadratic Interest Rate Volatility And Inflation H, Moderna Inc, BioNTech SE, Skyworks Solutions Inc, Aberdeen Standard Physical Precious Metals Basket during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Nvwm, Llc.

Yahoo | February 8, 2022

Were Hedge Funds Illusioned With Guardant Health, Inc. (GH)?

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors

Insider Monkey | February 7, 2022

Guardant Health to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., February 07, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating virtually in the following investor conferences.

Yahoo | February 7, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4643 seconds.